Image

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Comparing treatments for first-time extensive-stage small-cell lung cancer.

Recruiting
18-99 years
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study looks at how well a new drug, tarlatamab, works when used with other cancer drugs (durvalumab, carboplatin, and etoposide) for treating a type of lung cancer called extensive stage small-cell lung cancer (ES-SCLC). The goal is to see if the combination helps patients live longer. Patients must be at least 18 years old and have a specific stage of lung cancer. They need to be healthy enough to take the cancer drugs and have at least 12 weeks to live.

People cannot join the study if they have had another type of cancer in the last two years, have certain brain problems, or other severe health conditions. They also can't have certain infections like HIV or Hepatitis. The study will not accept those who've had a heart attack or some heart issues in the last six months.

  • The study is for adults with a specific lung cancer type.
  • Participants must be able to take the cancer drugs as a first treatment.
  • People with certain health issues or past cancers can't join.
Print
Study details
    Small-cell Lung Cancer
    Extensive Stage Small-cell Lung Cancer

NCT07005128

Amgen

18 April 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.